Results 191 to 200 of about 33,240 (248)

Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial. [PDF]

BMC Infect Dis
Zhou Y, Qin Y, Liu X, Zhao Q, Wang M, Chen Y, Li Y, He K, Li X, Harypursat V, Xie D, Chen Y.   +11 more
europepmc   +1 more source

Identification and structure-activity relationship analysis of minimal fusion inhibitors targeting measles virus F protein. [PDF]

RSC Med Chem
Kobayashi K, Yamaguchi Y, Itahara M, Hirata K, Aoki K, Iwamoto N, Hayashi H, Kodama E, Oishi S.   +8 more
europepmc   +1 more source

Beyond Antiretroviral Therapy: Molecular and Immunological Innovations in HIV Treatment. [PDF]

Trop Med Infect Dis
Alanazi A, Ibrahim MN, Elithy MA.
europepmc   +1 more source

Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies. [PDF]

Blood Cancer J
Li T, Wang C, Xiao Q, Zhang X, Yang Z, Li J, Liu Y.   +6 more
europepmc   +1 more source

Extracellular vesicles and viruses share a nuclear entry pathway in cancer and infection. [PDF]

Front Cell Dev Biol
Lorico A, Corbeil D.
europepmc   +1 more source

Antiviral Inflammasomes and How to Find Them. [PDF]

Viruses
Wuerth JD, Schmidt FI.
europepmc   +1 more source

Inflammation and RONS Dysregulation by Redox Enzymes as Mechanistic Links in HIV-1-Cancer Comorbidity. [PDF]

Pathogens
Ang CG, Eyunni S, Chaiken IM.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inhibitors of HIV cellular fusion

Expert Opinion on Therapeutic Patents, 2000
HIV infection continues to be a major global health problem. Current anti-HIV therapies targeting reverse transcriptase and protease enzymes suffer from high cost, a high probability of engendering resistance and adverse side effects following prolonged use. Thus, we are faced with the need to develop new antiviral strategies with more potent compounds
Jim A Turpin
exaly   +2 more sources